Patrick Phillips, PhD, MS, MA

Associate Professor
Co-Director, UC TRAC Clinical & Population Health Science Core
Medicine
[email protected]

The objective of my research is to design, implement, and optimize clinical trials for new treatments for drug-sensitive and drug-resistant tuberculosis in order to deliver safer and more efficacious regimens for patients. A key focus of my research has been to improve the design of TB clinical trials so that regimen development is faster and more efficient. This was motivated by my PhD thesis evaluating surrogate endpoints for TB trials, and has grown in a number of areas through the various collaborations and consortia that I contribute to. As Senior Statistician at the MRC Clinical Trials Unit at UCL, I have gained extensive experience as senior biostatistician of record for phase II and phase III clinical trials in both drug sensitive and drug resistant TB. I led the analyses of the REMoxTB and RIFAQUIN trials, published in the New England Journal of Medicine in 2014, and am senior statistician for the STREAM trials in MDR-TB that are ongoing. I have extended and implemented adaptive designs in clinical trials, most notable the Multi-Arm Multi-Stage (MAMS) design in the PanACEA MAMS-TB trial and the TRUNCATE-TB trial. Whereas my focus is primarily on TB trials, I have also worked in trials in Alzheimer’s disease and regularly contribute to the design and thinking of colleagues’ research in HIV and other infectious diseases of global significance. 

UCSF Center for Tuberculosis Leadership & Initiatives:
UC TRAC Clinical & Population Health Science Co-Director
TB RAMP Mentor / Executive Committee Member
SMART4TB UCSF Lead, Therapeutics 
World TB Day Oversight Planning Committee Member

Publications: 

Comparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: A single-center randomized trial.

PLoS medicine

Semitala FC, Kadota JL, Musinguzi A, Welishe F, Nakitende A, Akello L, Kunihira Tinka L, Nakimuli J, Ritar Kasidi J, Bishop O, Nakasendwa S, Baik Y, Patel D, Sammann A, Nahid P, Belknap R, Kamya MR, Handley MA, Phillips PP, Katahoire A, Berger CA, Kiwanuka N, Katamba A, Dowdy DW, Cattamanchi A

New manual qPCR assay validated on tongue swabs collected and processed in Uganda shows sensitivity that rivals sputum-based molecular TB diagnostics.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Steadman A, Andama A, Ball A, Mukwatamundu J, Khimani K, Mochizuki T, Asege L, Bukirwa A, Kato JB, Katumba D, Kisakye E, Mangeni W, Mwebe S, Nakaye M, Nassuna I, Nyawere J, Nakaweesa A, Cook C, Phillips P, Nalugwa T, Bachman CM, Semitala FC, Weigl BH, Connelly J, Worodria W, Cattamanchi A

Evaluation of the Xpert MTB Host Response assay for the triage of patients with presumed pulmonary tuberculosis: a prospective diagnostic accuracy study in Viet Nam, India, the Philippines, Uganda, and South Africa.

The Lancet. Global health

Gupta-Wright A, Ha H, Abdulgadar S, Crowder R, Emmanuel J, Mukwatamundu J, Marcelo D, Phillips PPJ, Christopher DJ, Nhung NV, Theron G, Yu C, Nahid P, Cattamanchi A, Worodria W, Denkinger CM, R2D2 TB Network

Cost effectiveness of low-complexity screening tests in community-based case-finding for tuberculosis.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Brümmer LE, Thompson RR, Malhotra A, Shrestha S, Kendall EA, Andrews JR, Phillips P, Nahid P, Cattamanchi A, Marx FM, Denkinger CM, Dowdy DW

Tuberculosis treatment monitoring tests during routine practice: study design guidance.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

MacLean EL, Zimmer AJ, Boon SD, Gupta-Wright A, Cirillo DM, Cobelens F, Gillespie SH, Nahid P, Phillips PP, Ruhwald M, Denkinger CM

Standards for clinical trials for treating TB.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease

du Cros P, Greig J, Alffenaar JC, Cross GB, Cousins C, Berry C, Khan U, Phillips PPJ, Velásquez GE, Furin J, Spigelman M, Denholm JT, Thi SS, Tiberi S, Huang GKL, Marks GB, Turkova A, Guglielmetti L, Chew KL, Nguyen HT, Ong CWM, Brigden G, Singh KP, Motta I, Lange C, Seddon JA, Nyang'wa BT, Maug AKJ, Gler MT, Dooley KE, Quelapio M, Tsogt B, Menzies D, Cox V, Upton CM, Skrahina A, McKenna L, Horsburgh CR, Dheda K, Marais BJ

Treatment-shortening regimens for tuberculosis: updates and future priorities.

Breathe (Sheffield, England)

Saluzzo F, Adepoju VA, Duarte R, Lange C, Phillips PPJ

Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis.

Antimicrobial agents and chemotherapy

Stemkens R, Jager V, Dawson R, Diacon AH, Narunsky K, Padayachee SD, Boeree MJ, van Beek SW, Colbers A, Coenen MJH, Svensson EM, Fuhr U, Phillips PPJ, Te Brake LHM, Aarnoutse RE, PanACEA consortium

A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxaci

Trials

Dierig A, Hoelscher M, Schultz S, Hoffmann L, Jarchow-MacDonald A, Svensson EM, Te Brake L, Aarnoutse R, Boeree M, McHugh TD, Wildner LM, Gong X, Phillips P, Minja LT, Ntinginya N, Mpagama S, Liyoyo A, Wallis RS, Sebe M, Mhimbira FA, Mbeya B, Rassool M, Geiter L, Cho YL, Heinrich N

Handling intercurrent events and missing data in non-inferiority trials using the estimand framework: A tuberculosis case study.

Clinical trials (London, England)

Rehal S, Cro S, Phillips PP, Fielding K, Carpenter JR

A Standardized Approach for Collection of Objective Data to Support Outcome Determination for Late-Phase TB Trials.

American journal of respiratory and critical care medicine

Kurbatova EV, Phillips PP, Dorman SE, Sizemore EE, Bryant KE, Purfield AE, Ricaldi J, Brown NE, Johnson JL, Wallis CL, Akol JP, Ocheretina O, Van Hung N, Mayanja-Kizza H, Lourens M, Dawson R, Nhung NV, Pierre S, Musodza Y, Shenje J, Badal-Faesen S, Vilbrun SC, Waja Z, Peddareddy L, Scott NA, Yuan Y, Vernon A, Goldberg SV, Swindells S, Chaisson RE, Nahid P, AIDS Clinical Trials Group and the Tuberculosis Trials Consortium

Protocol for a feasibility randomized controlled trial to evaluate the efficacy, safety and tolerability of N-acetylcysteine in reducing adverse drug reactions among adults treated for multidrug-resistant tuberculosis in Tanzania.

Pilot and feasibility studies

Mpagama SG, Mvungi HC, Mbelele PM, Semvua HH, Liyoyo AA, de Guex KP, Sloan D, Kibiki GS, Boeree M, Phillips PPJ, Heysell SK

Early bactericidal activity studies for pulmonary tuberculosis: A systematic review of methodological aspects.

International journal of antimicrobial agents

Koele SE, Phillips PPJ, Upton CM, van Ingen J, Simonsson USH, Diacon AH, Aarnoutse RE, Svensson EM

Rifapentine with and without moxifloxacin for pulmonary tuberculosis in people with HIV (S31/A5349).

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Pettit AC, Phillips PP, Kurbatova E, Vernon A, Nahid P, Dawson R, Dooley KE, Sanne I, Waja Z, Mohapi L, Podany AT, Samaneka W, Savic RM, Johnson JL, Muzanyi G, Lalloo UG, Bryant K, Sizemore E, Scott N, Dorman SE, Chaisson RE, Swindells S, Tuberculosis Trials Consortium (TBTC) Study 31/AIDS Clinical Trials Group (ACTG) A5349 study team

TB-Molecular Bacterial Load Assay reveals early delayed bacterial killing in relapse patients.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Ntinginya NE, Bakuli A, Mapamba D, Sabiiti W, Kibiki G, Minja LT, Kuchaka D, Reither K, Phillips PPJ, Boeree MJ, Gillespie SH, Hoelscher M, Heinrich N

Viral suppression among adults with HIV receiving routine dolutegravir-based antiretroviral therapy and 3HP.

AIDS (London, England)

Chaisson LH, Semitala FC, Nangobi F, Steinmetz S, Marquez C, Armstrong DT, Opira B, Kamya MR, Phillips PPJ, Dowdy DW, Yoon C

To Err Is Human, to Forgive Is Pharmacodynamic.

American journal of respiratory and critical care medicine

Phillips PPJ, Stout JE

A comparison of clinical development pathways to advance tuberculosis regimen development.

BMC infectious diseases

Chang V, Phillips PPJ, Imperial MZ, Nahid P, Savic RM

Efavirenz pharmacokinetics and HIV-1 viral suppression among patients receiving TB treatment containing daily high-dose rifapentine.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Podany AT, Pham M, Sizemore E, Martinson N, Samaneka W, Mohapi L, Badal-Faesen S, Dawson R, Johnson JL, Mayanja H, Lalloo U, Whitworth WC, Pettit A, Campbell K, Phillips P, Bryant K, Scott N, Vernon A, Kurbatova E, Chaisson RE, Dorman S, Nahid P, Swindells S, Dooley KE, Fletcher CV, AIDS Clinical Trials Group & Tuberculosis Trials Consortium

Factors associated with screening failure and study withdrawal in multidrug-resistant TB.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease

Schwalb A, Cachay R, Wright A, Phillips PPJ, Kaur P, Diacon AH, Ugarte-Gil C, Mitnick CD, Sterling TR, Gotuzzo E, Horsburgh CR

Rethinking intercurrent events in defining estimands for tuberculosis trials.

Clinical trials (London, England)

Pham TM, Tweed CD, Carpenter JR, Kahan BC, Nunn AJ, Crook AM, Esmail H, Goodall R, Phillips PP, White IR

Four-Month Rifapentine Regimens for Tuberculosis. Reply.

The New England journal of medicine

Phillips PPJ, Kurbatova EV, Dorman SE

Clinical Impact of the Line Probe Assay and Xpert® MTB/RIF Assay in the Presumptive Diagnosis of Drug-Resistant Tuberculosis in Brazil: A Pragmatic Clinical Trial.

Revista da Sociedade Brasileira de Medicina Tropical

Kritski A, Oliveira MM, Almeida IN, Ramalho D, Andrade MKN, Carvalho M, Miranda PFC, Dalcolmo MP, Braga JU, Brígido T, Mesquita E, Dias C, Gambirasio A, Souza Filho JB, Detjen A, Phillips PPJ, Langley I, Fujiwara P, Squire SB

MOVER approximated CV: A tool for quantifying precision in ratiometric droplet digital PCR assays.

Journal of pharmaceutical and biomedical analysis

Dide-Agossou C, Rossmassler K, Reid J, Purohit J, Savic RM, Nahid P, Phillips PPJ, Moore CM, Walter ND

Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial.

PLoS medicine

Semitala FC, Kadota JL, Musinguzi A, Nabunje J, Welishe F, Nakitende A, Akello L, Bishop O, Patel D, Sammann A, Nahid P, Belknap R, Kamya MR, Handley MA, Phillips PPJ, Katahoire A, Berger CA, Kiwanuka N, Katamba A, Dowdy DW, Cattamanchi A

Precision-enhancing Risk Stratification Tools for Selecting Optimal Treatment Durations in Tuberculosis Clinical Trials.

American journal of respiratory and critical care medicine

Imperial MZ, Phillips PPJ, Nahid P, Savic RM

Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial.

Trials

Guglielmetti L, Ardizzoni E, Atger M, Baudin E, Berikova E, Bonnet M, Chang E, Cloez S, Coit JM, Cox V, de Jong BC, Delifer C, Do JM, Tozzi DDS, Ducher V, Ferlazzo G, Gouillou M, Khan A, Khan U, Lachenal N, LaHood AN, Lecca L, Mazmanian M, McIlleron H, Moschioni M, O'Brien K, Okunbor O, Oyewusi L, Panda S, Patil SB, Phillips PPJ, Pichon L, Rupasinghe P, Rich ML, Saluhuddin N, Seung KJ, Tamirat M, Trippa L, Cellamare M, Velásquez GE, Wasserman S, Zimetbaum PJ, Varaine F, Mitnick CD

A systematic review of endpoint definitions in late phase pulmonary tuberculosis therapeutic trials.

Trials

Hills NK, Lyimo J, Nahid P, Savic RM, Lienhardt C, Phillips PPJ

Optimising pyrazinamide for the treatment of tuberculosis.

The European respiratory journal

Zhang N, Savic RM, Boeree MJ, Peloquin C, Weiner M, Heinrich N, Bliven-Sizemore E, Phillips PP, Hoelscher M, Whitworth W, Morlock G, Posey J, Stout JE, Mac Kenzie W, Aarnoutse R, Dooley KE

Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg-1 rifampicin.

The European respiratory journal

Te Brake LHM, de Jager V, Narunsky K, Vanker N, Svensson EM, Phillips PPJ, Gillespie SH, Heinrich N, Hoelscher M, Dawson R, Diacon AH, Aarnoutse RE, Boeree MJ

Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.

The New England journal of medicine

Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, Engle M, Goldberg SV, Phan HTT, Hakim J, Johnson JL, Lourens M, Martinson NA, Muzanyi G, Narunsky K, Nerette S, Nguyen NV, Pham TH, Pierre S, Purfield AE, Samaneka W, Savic RM, Sanne I, Scott NA, Shenje J, Sizemore E, Vernon A, Waja Z, Weiner M, Swindells S, Chaisson RE, AIDS Clinical Trials Group , Tuberculosis Trials Consortium

Mycobactericidal effect of different regimens measured by molecular bacterial load assay among people treated for multidrug-resistant tuberculosis in Tanzania.

Journal of clinical microbiology

Mbelele PM, Mpolya EA, Sauli E, Mtafya B, Ntinginya NE, Addo KK, Kreppel K, Mfinanga S, Phillips PPJ, Gillespie SH, Heysell SK, Sabiiti W, Mpagama SG

The use of molecular genetic diagnostic tests to improve MDR TB treatment outcomes in Arkhangelsk Region

Tuberculosis and Lung Diseases

Eliseev, P. I.; Maryandyshev, A. O.; Detjen, A.; Dacombe, R.; Squire, S. B.; Phillips, P.

Investigation of the efficacy of the short regimen for rifampicin-resistant TB from the STREAM trial.

BMC medicine

Phillips PPJ, Van Deun A, Ahmed S, Goodall RL, Meredith SK, Conradie F, Chiang CY, Rusen ID, Nunn AJ

Protocol for the 3HP Options Trial: a hybrid type 3 implementation-effectiveness randomized trial of delivery strategies for short-course tuberculosis preventive therapy among people living with HIV in Uganda.

Implementation science : IS

Kadota JL, Musinguzi A, Nabunje J, Welishe F, Ssemata JL, Bishop O, Berger CA, Patel D, Sammann A, Katahoire A, Nahid P, Belknap R, Phillips PPJ, Namusobya J, Kamya M, Handley MA, Kiwanuka N, Katamba A, Dowdy D, Semitala FC, Cattamanchi A

Reply to Swindells et al.: Trials of Tuberculosis-Preventive Therapy in People with HIV Infection.

American journal of respiratory and critical care medicine

Stout JE, Turner NA, Belknap RW, Horsburgh CR, Sterling TR, Phillips PPJ

Tuberculosis bacillary load, an early marker of disease severity: the utility of tuberculosis Molecular Bacterial Load Assay.

Thorax

Sabiiti W, Azam K, Farmer ECW, Kuchaka D, Mtafya B, Bowness R, Oravcova K, Honeyborne I, Evangelopoulos D, McHugh TD, Khosa C, Rachow A, Heinrich N, Kampira E, Davies G, Bhatt N, Ntinginya EN, Viegas S, Jani I, Kamdolozi M, Mdolo A, Khonga M, Boeree MJ, Phillips PPJ, Sloan D, Hoelscher M, Kibiki G, Gillespie SH

Optimizing the Design of Latent Tuberculosis Treatment Trials: Insights from Mathematical Modeling.

American journal of respiratory and critical care medicine

Stout JE, Turner NA, Belknap RW, Horsburgh CR, Sterling TR, Phillips PPJ

Economic evaluation of short treatment for multidrug-resistant tuberculosis, Ethiopia and South Africa: the STREAM trial.

Bulletin of the World Health Organization

Madan JJ, Rosu L, Tefera MG, van Rensburg C, Evans D, Langley I, Tomeny EM, Nunn A, Phillips PP, Rusen ID, Squire SB

High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial.

Contemporary clinical trials

Dorman SE, Nahid P, Kurbatova EV, Goldberg SV, Bozeman L, Burman WJ, Chang KC, Chen M, Cotton M, Dooley KE, Engle M, Feng PJ, Fletcher CV, Ha P, Heilig CM, Johnson JL, Lessem E, Metchock B, Miro JM, Nhung NV, Pettit AC, Phillips PPJ, Podany AT, Purfield AE, Robergeau K, Samaneka W, Scott NA, Sizemore E, Vernon A, Weiner M, Swindells S, Chaisson RE

Fluoroquinolones and isoniazid-resistant tuberculosis: implications for the 2018 WHO guidance.

The European respiratory journal

Stagg HR, Bothamley GH, Davidson JA, Kunst H, Lalor MK, Lipman MC, Loutet MG, Lozewicz S, Mohiyuddin T, Abbara A, Alexander E, Booth H, Creer DD, Harris RJ, Kon OM, Loebinger MR, McHugh TD, Milburn HJ, Palchaudhuri P, Phillips PPJ, Schmok E, Taylor L, Abubakar I

Proposals on Kaplan-Meier plots in medical research and a survey of stakeholder views: KMunicate.

BMJ open

Morris TP, Jarvis CI, Cragg W, Phillips PPJ, Choodari-Oskooei B, Sydes MR

A Shorter Regimen for Rifampin-Resistant Tuberculosis. Reply.

The New England journal of medicine

Nunn AJ, Phillips PPJ

Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status.

BMC pulmonary medicine

Tweed CD, Crook AM, Dawson R, Diacon AH, McHugh TD, Mendel CM, Meredith SK, Mohapi L, Murphy ME, Nunn AJ, Phillips PPJ, Singh KP, Spigelman M, Gillespie SH

STREAM: a pragmatic and explanatory trial for MDR-TB treatment.

The Lancet. Infectious diseases

Abubakar I, Meredith S, Nunn AJ, Phillips PPJ, Rusen ID

Feasibility of Direct Sputum Molecular Testing for Drug Resistance as Part of Tuberculosis Clinical Trials Eligibility Screening.

Diagnostics (Basel, Switzerland)

Alipanah N, Shete PB, Nguyen H, Nguyen NV, Luu L, Pham T, Nguyen H, Nguyen P, Tran MC, Pham N, Phan H, Phillips PPJ, Cattamanchi A, Nahid P

Protein binding of rifampicin is not saturated when using high-dose rifampicin.

The Journal of antimicrobial chemotherapy

Litjens CHC, Aarnoutse RE, van Ewijk-Beneken Kolmer EWJ, Svensson EM, Colbers A, Burger DM, Boeree MJ, Te Brake LHM, PanACEA-MAMS-TB-01 Team

Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape.

PLoS medicine

Phillips PPJ, Mitnick CD, Neaton JD, Nahid P, Lienhardt C, Nunn AJ

A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis.

The New England journal of medicine

Nunn AJ, Phillips PPJ, Meredith SK, Chiang CY, Conradie F, Dalai D, van Deun A, Dat PT, Lan N, Master I, Mebrahtu T, Meressa D, Moodliar R, Ngubane N, Sanders K, Squire SB, Torrea G, Tsogt B, Rusen ID

Cost minimization analysis of line probe assay for detection of multidrug-resistant tuberculosis in Arkhangelsk region of Russian Federation.

PloS one

Bogdanova EN, Mariandyshev AO, Balantcev GA, Eliseev PI, Nikishova EI, Gaida AI, Enarson D, Detjen A, Dacombe R, Phillips PPJ, Squire SB, Gospodarevskaya E

Publisher Correction: A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis.

Nature medicine

Imperial MZ, Nahid P, Phillips PPJ, Davies GR, Fielding K, Hanna D, Hermann D, Wallis RS, Johnson JL, Lienhardt C, Savic RM

A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis.

Nature medicine

Imperial MZ, Nahid P, Phillips PPJ, Davies GR, Fielding K, Hanna D, Hermann D, Wallis RS, Johnson JL, Lienhardt C, Savic RM

Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis.

Antimicrobial agents and chemotherapy

Peloquin CA, Phillips PPJ, Mitnick CD, Eisenach K, Patientia RF, Lecca L, Gotuzzo E, Gandhi NR, Butler D, Diacon AH, Martel B, Santillan J, Hunt KR, Vargas D, von Groote-Bidlingmaier F, Seas C, Dianis N, Moreno-Martinez A, Kaur P, Horsburgh CR

Toxicity associated with tuberculosis chemotherapy in the REMoxTB study.

BMC infectious diseases

Tweed CD, Crook AM, Amukoye EI, Dawson R, Diacon AH, Hanekom M, McHugh TD, Mendel CM, Meredith SK, Murphy ME, Murthy SE, Nunn AJ, Phillips PPJ, Singh KP, Spigelman M, Wills GH, Gillespie SH

The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Svensson EM, Svensson RJ, Te Brake LHM, Boeree MJ, Heinrich N, Konsten S, Churchyard G, Dawson R, Diacon AH, Kibiki GS, Minja LT, Ntingiya NE, Sanne I, Gillespie SH, Hoelscher M, Phillips PPJ, Simonsson USH, Aarnoutse R

Rethinking non-inferiority: a practical trial design for optimising treatment duration.

Clinical trials (London, England)

Quartagno M, Walker AS, Carpenter JR, Phillips PP, Parmar MK

Pretreatment chest x-ray severity and its relation to bacterial burden in smear positive pulmonary tuberculosis.

BMC medicine

Murthy SE, Chatterjee F, Crook A, Dawson R, Mendel C, Murphy ME, Murray SR, Nunn AJ, Phillips PPJ, Singh KP, McHugh TD, Gillespie SH

Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis.

The Lancet. Respiratory medicine

Fregonese F, Ahuja SD, Akkerman OW, Arakaki-Sanchez D, Ayakaka I, Baghaei P, Bang D, Bastos M, Benedetti A, Bonnet M, Cattamanchi A, Cegielski P, Chien JY, Cox H, Dedicoat M, Erkens C, Escalante P, Falzon D, Garcia-Prats AJ, Gegia M, Gillespie SH, Glynn JR, Goldberg S, Griffith D, Jacobson KR, Johnston JC, Jones-López EC, Khan A, Koh WJ, Kritski A, Lan ZY, Lee JH, Li PZ, Maciel EL, Galliez RM, Merle CSC, Munang M, Narendran G, Nguyen VN, Nunn A, Ohkado A, Park JS, Phillips PPJ, Ponnuraja C, Reves R, Romanowski K, Seung K, Schaaf HS, Skrahina A, Soolingen DV, Tabarsi P, Trajman A, Trieu L, Banurekha VV, Viiklepp P, Wang JY, Yoshiyama T, Menzies D

Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study.

BMC medicine

Tweed CD, Wills GH, Crook AM, Dawson R, Diacon AH, Louw CE, McHugh TD, Mendel C, Meredith S, Mohapi L, Murphy ME, Murray S, Murthy S, Nunn AJ, Phillips PPJ, Singh K, Spigelman M, Gillespie SH

An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial.

Trials

Bouton TC, Phillips PPJ, Mitnick CD, Peloquin CA, Eisenach K, Patientia RF, Lecca L, Gotuzzo E, Gandhi NR, Butler D, Diacon AH, Martel B, Santillan J, Hunt KR, Vargas D, von Groote-Bidlingmaier F, Seas C, Dianis N, Moreno-Martinez A, Horsburgh CR

A comparison of liquid and solid culture for determining relapse and durable cure in phase III TB trials for new regimens.

BMC medicine

Phillips PPJ, Mendel CM, Nunn AJ, McHugh TD, Crook AM, Hunt R, Bateson A, Gillespie SH

Spot sputum samples are at least as good as early morning samples for identifying Mycobacterium tuberculosis.

BMC medicine

Murphy ME, Phillips PPJ, Mendel CM, Bongard E, Bateson ALC, Hunt R, Murthy S, Singh KP, Brown M, Crook AM, Nunn AJ, Meredith SK, Lipman M, McHugh TD, Gillespie SH

Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis.

Antimicrobial agents and chemotherapy

Aarnoutse RE, Kibiki GS, Reither K, Semvua HH, Haraka F, Mtabho CM, Mpagama SG, van den Boogaard J, Sumari-de Boer IM, Magis-Escurra C, Wattenberg M, Logger JGM, Te Brake LHM, Hoelscher M, Gillespie SH, Colbers A, Phillips PPJ, Plemper van Balen G, Boeree MJ

Testing many treatments within a single protocol over 10?years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols.

Clinical trials (London, England)

Parmar MK, Sydes MR, Cafferty FH, Choodari-Oskooei B, Langley RE, Brown L, Phillips PP, Spears MR, Rowley S, Kaplan R, James ND, Maughan T, Paton N, Royston PJ

Outcomes from patients with presumed drug resistant tuberculosis in five reference centers in Brazil.

BMC infectious diseases

Ramalho DMP, Miranda PFC, Andrade MK, Brígido T, Dalcolmo MP, Mesquita E, Dias CF, Gambirasio AN, Ueleres Braga J, Detjen A, Phillips PPJ, Langley I, Fujiwara PI, Squire SB, Oliveira MM, Kritski AL

Setting Tuberculosis Regimen Development on a Firm Foundation.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Phillips PPJ

Use of whole-genome sequencing to distinguish relapse from reinfection in a completed tuberculosis clinical trial.

BMC medicine

Witney AA, Bateson AL, Jindani A, Phillips PP, Coleman D, Stoker NG, Butcher PD, McHugh TD

Methodological considerations in clinical trials for new MDR-TB treatment regimens.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease

Phillips PPJ

High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.

The Lancet. Infectious diseases

Boeree MJ, Heinrich N, Aarnoutse R, Diacon AH, Dawson R, Rehal S, Kibiki GS, Churchyard G, Sanne I, Ntinginya NE, Minja LT, Hunt RD, Charalambous S, Hanekom M, Semvua HH, Mpagama SG, Manyama C, Mtafya B, Reither K, Wallis RS, Venter A, Narunsky K, Mekota A, Henne S, Colbers A, van Balen GP, Gillespie SH, Phillips PPJ, Hoelscher M

Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial).

International journal of geriatric psychiatry

Knapp M, King D, Romeo R, Adams J, Baldwin A, Ballard C, Banerjee S, Barber R, Bentham P, Brown RG, Burns A, Dening T, Findlay D, Holmes C, Johnson T, Jones R, Katona C, Lindesay J, Macharouthu A, McKeith I, McShane R, O'Brien JT, Phillips PPJ, Sheehan B, Howard R

Non-inferiority trials: are they inferior? A systematic review of reporting in major medical journals.

BMJ open

Rehal S, Morris TP, Fielding K, Carpenter JR, Phillips PP

Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China.

The European respiratory journal

Berry C, Yates TA, Seddon JA, Phillips PP, du Cros P

The Impact of a Line Probe Assay Based Diagnostic Algorithm on Time to Treatment Initiation and Treatment Outcomes for Multidrug Resistant TB Patients in Arkhangelsk Region, Russia.

PloS one

Eliseev P, Balantcev G, Nikishova E, Gaida A, Bogdanova E, Enarson D, Ornstein T, Detjen A, Dacombe R, Gospodarevskaya E, Phillips PP, Mann G, Squire SB, Mariandyshev A

A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP).

BMC medicine

Phillips PP, Dooley KE, Gillespie SH, Heinrich N, Stout JE, Nahid P, Diacon AH, Aarnoutse RE, Kibiki GS, Boeree MJ, Hoelscher M

World TB Day 2016: an interview with leading experts in tuberculosis research.

BMC medicine

Phillips PP, Fletcher HA, Abubakar I, Lipman MC, McHugh TD

Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease

Furin J, Alirol E, Allen E, Fielding K, Merle C, Abubakar I, Andersen J, Davies G, Dheda K, Diacon A, Dooley KE, Dravnice G, Eisenach K, Everitt D, Ferstenberg D, Goolam-Mahomed A, Grobusch MP, Gupta R, Harausz E, Harrington M, Horsburgh CR, Lienhardt C, McNeeley D, Mitnick CD, Nachman S, Nahid P, Nunn AJ, Phillips P, Rodriguez C, Shah S, Wells C, Thomas-Nyang'wa B, du Cros P

Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials.

BMC medicine

Phillips PP, Mendel CM, Burger DA, Crook AM, Crook A, Nunn AJ, Dawson R, Diacon AH, Gillespie SH

Challenges in the clinical assessment of novel tuberculosis drugs.

Advanced drug delivery reviews

Dooley KE, Phillips PP, Nahid P, Hoelscher M

DOOR/RADAR: A Gateway Into the Unknown?

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Phillips PP, Morris TP, Walker AS

Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses.

The Lancet. Neurology

Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, Burns A, Dening T, Findlay D, Holmes C, Jones R, Jones R, McKeith I, Macharouthu A, O'Brien J, Sheehan B, Juszczak E, Katona C, Hills R, Knapp M, Ballard C, Brown RG, Banerjee S, Adams J, Johnson T, Bentham P, Phillips PP

Reducing relapse in tuberculosis treatment.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease

Nunn AJ, Phillips PP, Abubakar I

A Step toward an Optimized Rifampin Dose Completed.

American journal of respiratory and critical care medicine

Boeree MJ, Diacon AH, Dawson R, Narunsky K, du Bois J, Venter A, Phillips PP, Gillespie SH, McHugh TD, Hoelscher M, Heinrich N, Rehal S, van Soolingen D, van Ingen J, Magis-Escurra C, Burger D, Plemper van Balen G, Aarnoutse RE

Comments on 'A modest proposal for dropping poor arms in clinical trials' by Proschan and Dodd.

Statistics in medicine

Bratton DJ, Choodari-Oskooei B, Phillips PP, Sydes MR, Parmar MK

Adaptive clinical trials in tuberculosis: applications, challenges and solutions.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease

Davies GR, Phillips PP, Jaki T

A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.

American journal of respiratory and critical care medicine

Boeree MJ, Diacon AH, Dawson R, Narunsky K, du Bois J, Venter A, Phillips PP, Gillespie SH, McHugh TD, Hoelscher M, Heinrich N, Rehal S, van Soolingen D, van Ingen J, Magis-Escurra C, Burger D, Plemper van Balen G, Aarnoutse RE

Safe and effective treatment for patients with isoniazid drug resistance.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease

Phillips PP, Lipman MC

Shorter moxifloxacin-based regimens for drug-sensitive tuberculosis.

The New England journal of medicine

Alffenaar JW, Gumbo T, Aarnoutse R

Shorter moxifloxacin-based regimens for drug-sensitive tuberculosis.

The New England journal of medicine

Gillespie SH, Mendel CM

Shorter moxifloxacin-based regimens for drug-sensitive tuberculosis.

The New England journal of medicine

Sellier PO, Clevenbergh P, Bergmann JF

Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients.

The Journal of antimicrobial chemotherapy

Heinrich N, Dawson R, du Bois J, Narunsky K, Horwith G, Phipps AJ, Nacy CA, Aarnoutse RE, Boeree MJ, Gillespie SH, Venter A, Henne S, Rachow A, Phillips PP, Hoelscher M, Diacon AH

Shortening treatment of tuberculosis: lessons from fluoroquinolone trials.

The Lancet. Infectious diseases

Nimmo C, Lipman M, Phillips PP, McHugh T, Nunn A, Abubakar I

The relationship between Mycobacterium tuberculosis MGIT time to positivity and cfu in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populations.

The Journal of antimicrobial chemotherapy

Bowness R, Boeree MJ, Aarnoutse R, Dawson R, Diacon A, Mangu C, Heinrich N, Ntinginya NE, Kohlenberg A, Mtafya B, Phillips PP, Rachow A, Plemper van Balen G, Gillespie SH

High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.

The New England journal of medicine

Jindani A, Harrison TS, Nunn AJ, Phillips PP, Churchyard GJ, Charalambous S, Hatherill M, Geldenhuys H, McIlleron HM, Zvada SP, Mungofa S, Shah NA, Zizhou S, Magweta L, Shepherd J, Nyirenda S, van Dijk JH, Clouting HE, Coleman D, Bateson AL, McHugh TD, Butcher PD, Mitchison DA

Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.

The New England journal of medicine

Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, Pappas F, Phillips PP, Nunn AJ

Short intensified treatment in children with drug-susceptible tuberculous meningitis.

The Pediatric infectious disease journal

Turkova A, Seddon JA, Nunn AJ, Gibb DM, Phillips PP

The molecular bacterial load assay replaces solid culture for measuring early bactericidal response to antituberculosis treatment.

Journal of clinical microbiology

Honeyborne I, Mtafya B, Phillips PP, Hoelscher M, Ntinginya EN, Kohlenberg A, Rachow A, Rojas-Ponce G, McHugh TD, Heinrich N

New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects.

The Lancet. Infectious diseases

Zumla AI, Gillespie SH, Hoelscher M, Philips PP, Cole ST, Abubakar I, McHugh TD, Schito M, Maeurer M, Nunn AJ

A multi-arm multi-stage clinical trial design for binary outcomes with application to tuberculosis.

BMC medical research methodology

Bratton DJ, Phillips PP, Parmar MK

Principles for designing future regimens for multidrug-resistant tuberculosis.

Bulletin of the World Health Organization

Brigden G, Nyang'wa BT, du Cros P, Varaine F, Hughes J, Rich M, Horsburgh CR, Mitnick CD, Nuermberger E, McIlleron H, Phillips PP, Balasegaram M

Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment.

The Lancet. Respiratory medicine

Friedrich SO, Rachow A, Saathoff E, Singh K, Mangu CD, Dawson R, Phillips PP, Venter A, Bateson A, Boehme CC, Heinrich N, Hunt RD, Boeree MJ, Zumla A, McHugh TD, Gillespie SH, Diacon AH, Hoelscher M

An analysis with serious flaws.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Nunn AJ, Phillips PP

Is a 4-month regimen adequate to cure patients with non-cavitary tuberculosis and negative cultures at 2 months?

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease

Phillips PP, Nunn AJ, Paton NI

Treatment of pulmonary tuberculosis.

Current opinion in pulmonary medicine

Nunn A, Phillips PP, Abubakar I

Randomized clinical trials to identify optimal antibiotic treatment duration.

Trials

Horsburgh CR, Shea KM, Phillips P, Lavalley M

Reply to Dodd and Proschan.

The Journal of infectious diseases

Phillips PP, Bratton DJ, Nunn AJ, Hoelscher M

When inferiority meets non-inferiority: implications for interim analyses.

Clinical trials (London, England)

Bratton DJ, Williams HC, Kahan BC, Phillips PP, Nunn AJ

Innovative trial designs are practical solutions for improving the treatment of tuberculosis.

The Journal of infectious diseases

Phillips PP, Gillespie SH, Boeree M, Heinrich N, Aarnoutse R, McHugh T, Pletschette M, Lienhardt C, Hafner R, Mgone C, Zumla A, Nunn AJ, Hoelscher M

Donepezil and memantine for moderate-to-severe Alzheimer's disease.

The New England journal of medicine

Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, Burns A, Dening T, Findlay D, Holmes C, Hughes A, Jacoby R, Jones R, Jones R, McKeith I, Macharouthu A, O'Brien J, Passmore P, Sheehan B, Juszczak E, Katona C, Hills R, Knapp M, Ballard C, Brown R, Banerjee S, Onions C, Griffin M, Adams J, Gray R, Johnson T, Bentham P, Phillips P

CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap.

American journal of respiratory and critical care medicine

Nahid P, Saukkonen J, Mac Kenzie WR, Johnson JL, Phillips PP, Andersen J, Bliven-Sizemore E, Belisle JT, Boom WH, Luetkemeyer A, Campbell TB, Eisenach KD, Hafner R, Lennox JL, Makhene M, Swindells S, Villarino ME, Weiner M, Benson C, Burman W

Molecular bacterial load assay, a culture-free biomarker for rapid and accurate quantification of sputum Mycobacterium tuberculosis bacillary load during treatment.

Journal of clinical microbiology

Honeyborne I, McHugh TD, Phillips PP, Bannoo S, Bateson A, Carroll N, Perrin FM, Ronacher K, Wright L, van Helden PD, Walzl G, Gillespie SH

Radiological cavitation, sputum mycobacterial load and treatment response in pulmonary tuberculosis.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease

Perrin FM, Woodward N, Phillips PP, McHugh TD, Nunn AJ, Lipman MC, Gillespie SH

Determining the minimum clinically important differences for outcomes in the DOMINO trial.

International journal of geriatric psychiatry

Howard R, Phillips P, Johnson T, O'Brien J, Sheehan B, Lindesay J, Bentham P, Burns A, Ballard C, Holmes C, McKeith I, Barber R, Dening T, Ritchie C, Jones R, Baldwin A, Passmore P, Findlay D, Hughes A, Macharouthu A, Banerjee S, Jones R, Knapp M, Brown RG, Jacoby R, Adams J, Griffin M, Gray R

Bactericidal activity of the diarylquinoline TMC207 against Mycobacterium tuberculosis outside and within cells.

Tuberculosis (Edinburgh, Scotland)

Dhillon J, Andries K, Phillips PP, Mitchison DA

Impact of cotrimoxazole on carriage and antibiotic resistance of Streptococcus pneumoniae and Haemophilus influenzae in HIV-infected children in Zambia.

Antimicrobial agents and chemotherapy

Mwenya DM, Charalambous BM, Phillips PP, Mwansa JC, Batt SL, Nunn AJ, Walker S, Gibb DM, Gillespie SH

Biomarkers for tuberculosis disease activity, cure, and relapse.

The Lancet. Infectious diseases

Phillips PP, Davies GR, Mitchison DA

Timing of relapse in short-course chemotherapy trials for tuberculosis.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease

Nunn AJ, Phillips PP, Mitchison DA

DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT.

Trials

Jones R, Sheehan B, Phillips P, Juszczak E, Adams J, Baldwin A, Ballard C, Banerjee S, Barber B, Bentham P, Brown R, Burns A, Dening T, Findlay D, Gray R, Griffin M, Holmes C, Hughes A, Jacoby R, Johnson T, Jones R, Knapp M, Lindesay J, McKeith I, McShane R, Macharouthu A, O'Brien J, Onions C, Passmore P, Raftery J, Ritchie C, Howard R

Design issues in pivotal drug trials for drug sensitive tuberculosis (TB).

Tuberculosis (Edinburgh, Scotland)

Nunn AJ, Phillips PP, Gillespie SH

Biomarkers and surrogate end points in clinical trials of tuberculosis treatment.

The Journal of infectious diseases

Davies GR, Phillips PP, Nunn AJ

Cannabis in postoperative pain: a pharmacokinetic study

British Journal of Anaesthesia

A. Holdcroft, C. Dore, P. Phillips, M. Maze and M. Hanna